The anti-inflammatory effects of remimazolam on cardiopulmonary bypass and its impact on pancreatic cancer.

The anti-inflammatory effects of remimazolam on cardiopulmonary bypass and its impact on pancreatic cancer: A randomized controlled study.

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1031260169

Enrollment

Registered

2026-06-01

Start date

2026-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

This study targets patients undergoing cardiac surgery under general anesthesia in the central opera

Interventions

Patients will be randomly assigned to either the remimazolam group (usual sedative management (sevoflurane before and after cardiopulmonary bypass, propofol during cardiopulmonary bypass) + remimazola

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients aged 20 years or older at the time of obtaining consent (pre-operative consultation) 2) Cases with an American Society of Anesthesiologists (ASA) pre-anesthetic risk assessment of 4 or less (ASA classification: 1: No organic, physiological, biochemical, or psychiatric abnormalities. 2: Mild to moderate systemic impairment. 3: Severe systemic impairment. 4: Severe systemic disease that is life-threatening and may not be curable by surgery. 5: Critically ill.) 3) Patients undergoing cardiac surgery under cardiopulmonary bypass 4) Individuals who have received a thorough explanation of participation in this study at the pre-operative consultation, fully understood the information, and provided written consent of their own free will.

Exclusion criteria

Exclusion criteria: 1) Patients with cancer or a history of surgery for malignant tumors 2) Patients with poorly controlled diabetes (HbA1c > 8.0%) 3) Patients with severe renal impairment (eGFR < 30%) 4) Patients with severe hepatic impairment (Child-Pugh C or higher) 5) Patients taking steroids orally 6) Patients with inflammatory diseases or infectious symptoms (surgery for infective endocarditis) 7) Cases requiring re-induction of CPB, cases of circulatory arrest, and cases where aortic clamping was not performed 8) Cases requiring emergency surgery 9) Other patients deemed unsuitable as research subjects by the principal investigator 10) Individuals who have refused to participate in this study

Design outcomes

Primary

Measure	Time frame
Changes in inflammatory cytokines in plasma	—

Secondary

Measure	Time frame
Proliferative capacity of human pancreatic cancer cells Metastatic and invasive capacity of human pancreatic cancer cells Changes in chemokines and growth factors	—

Contacts

Public ContactTomoaki Itaya

Nihon University School of Medicine Itabashi Hospital

itaya.tomoaki@nihon-u.ac.jp+81-3-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026